1. Home
  2. INDP vs ULY Comparison

INDP vs ULY Comparison

Compare INDP & ULY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INDP
  • ULY
  • Stock Information
  • Founded
  • INDP 2000
  • ULY 2013
  • Country
  • INDP United States
  • ULY United States
  • Employees
  • INDP N/A
  • ULY N/A
  • Industry
  • INDP Biotechnology: Pharmaceutical Preparations
  • ULY
  • Sector
  • INDP Health Care
  • ULY
  • Exchange
  • INDP Nasdaq
  • ULY Nasdaq
  • Market Cap
  • INDP 6.0M
  • ULY 6.3M
  • IPO Year
  • INDP N/A
  • ULY N/A
  • Fundamental
  • Price
  • INDP $2.41
  • ULY $4.01
  • Analyst Decision
  • INDP Strong Buy
  • ULY Strong Buy
  • Analyst Count
  • INDP 2
  • ULY 2
  • Target Price
  • INDP $238.00
  • ULY $11.50
  • AVG Volume (30 Days)
  • INDP 199.1K
  • ULY 90.2K
  • Earning Date
  • INDP 11-11-2025
  • ULY 11-11-2025
  • Dividend Yield
  • INDP N/A
  • ULY N/A
  • EPS Growth
  • INDP N/A
  • ULY N/A
  • EPS
  • INDP N/A
  • ULY N/A
  • Revenue
  • INDP N/A
  • ULY $131,235,000.00
  • Revenue This Year
  • INDP N/A
  • ULY N/A
  • Revenue Next Year
  • INDP N/A
  • ULY $20.23
  • P/E Ratio
  • INDP N/A
  • ULY N/A
  • Revenue Growth
  • INDP N/A
  • ULY N/A
  • 52 Week Low
  • INDP $2.22
  • ULY $2.99
  • 52 Week High
  • INDP $58.24
  • ULY $17.99
  • Technical
  • Relative Strength Index (RSI)
  • INDP 22.05
  • ULY 39.32
  • Support Level
  • INDP $2.22
  • ULY $3.70
  • Resistance Level
  • INDP $2.86
  • ULY $4.29
  • Average True Range (ATR)
  • INDP 0.67
  • ULY 0.39
  • MACD
  • INDP -0.18
  • ULY 0.05
  • Stochastic Oscillator
  • INDP 3.86
  • ULY 32.35

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

Share on Social Networks: